Daiichi Sankyo Prioritizes R&D On Thrombosis And Three Other Areas
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo unveiled a new business strategy at an Oct. 8 conference in Tokyo. The strategy includes prioritizing research and development resources to antibody drug denosumab and CS-8635, a three-drug combination hypertension treatment. The company has identified four research areas as growth engines to focus R&D resources: thrombosis, cancer, diabetes and arthritis. In the thrombosis area, the company plans to focus on antiplalelet and anticlotting drugs. Oral anti-Xa drug DU-176b has completed Phase II trials in Japan, Europe and the U.S., and international joint Phase III trials will start in November. At the meeting, Daiichi Sankyo also disclosed the company's decision to halt developing antiplatelet drug DZ-697b. (Click here for more - Japanese language